Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 10, 2025 04:00 ET | Source: Alvotech

Alvotech vinnur sigur í mikilvægu dómsmáli um framleiðslu og markaðssetningu AVT06 hliðstæðunnar við Eylea (aflibercept)

Alvotech (NASDAQ: ALVO, ALVO SDB) tilkynnti í dag að dómstóll í Bretlandi hafi hafnað lögbannskröfu Regeneron Pharmaceuticals og Bayer sem beindist að Alvotech og þjónustuaðila félagsins í Bretlandi....
November 10, 2025 04:00 ET | Source: Alvotech

UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)

REYKJAVIK, ICELAND (November 10, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced...
November 06, 2025 09:00 ET | Source: Alvotech

Alvotech og Advanz Pharma fá markaðsleyfi í Bretlandi fyrir Gobivaz, hliðstæðu við Simponi (golimumab)

REYKJAVÍK OG LONDON (6. OKTÓBER 2025) - Breska lyfjastofnunin (MHRA) hefur veitt markaðsleyfi fyrir allar útgáfur Gobivaz, hliðstæðu Alvotech við líftæknilyfið Simponi (golimumab). Samstarfsaðili...
November 06, 2025 09:00 ET | Source: Alvotech

Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA

REYKJAVIK, ICELAND and LONDON, UK (November 06, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide...
April 30, 2024 04:00 ET | Source: Alvotech

U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)

Alvotech will manufacture its high-concentration interchangeable biosimilar to Humira® (adalimumab) for Quallent Pharmaceuticals The strategic agreement is in alignment with Alvotech’s U.S....
February 24, 2020 12:08 ET | Source: Open Minds

82% Of States Suspend Medicaid Benefits For Incarcerated Populations: OPEN MINDS Releases Update On Inmate Medicaid Benefits

Gettysburg, Pa, Feb. 24, 2020 (GLOBE NEWSWIRE) -- A new report by OPEN MINDS, State Policy On Medicaid Benefits For State Prison Inmates: A State-By-State Review, found that 42 states (82%) suspend,...